NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

“AND that technology is DCVax-L!!!! AND the availability does not result from an uplist to a legitimate exchange, it results from a final MHRA marketing approval and the sale to or partnership with a major biotech that understands the future of healthcare is immunotherapy vaccines AND has the existing infrastructure to accelerate patient delivery!!

—-I agree with your above analysis, but I don’t think it will be a buyout. Likely a partnership early on post MHRA approval because scaling up personalized vaccine manufacturing and ramping up of commercial revenues will take time. So the acquiring biotech company would likely want to wait another couple of years to see how things develop commercially before they make an aggressive buyout offer. If buyout was imminent post MHRA approval, they wouldn’t have issued 100M C shares (equivalent to 250M common shares) in December, I think.